
    
      The primary objective of this study will be to compare the overall efficacy and safety of AES
      ( Activation Energy Serum) by demonstrating a clinically significant improvement in morning
      FEV1 in patients with mild to moderate persistent asthma treated with 2 doses of AES for 4
      weeks compared to placebo.

      The secondary objectives will be to evaluate the effect of AES on a) clinical symptoms by
      symptom scores and the Asthma Control Questionnaire ( ACQ) , b) fractional exhaled nitric
      oxide ( FeNO) , c) blood eosinophil count and other biomarkers , and d) quality of life
      through the Asthma Quality of Life Questionnaire ( AQLQ) .
    
  